Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Inclusion Criteria: * History of biopsy documented prostate cancer (any Gleason score) * Past treatment with prostatectomy with or without salvage prostate/pelvic radiation or primary radiation (external beam or brachytherapy) * If past prostatectomy, pathologic stage no greater than T1-3, N1, M0 * PSA recurrence with PSAdt \< 18 months. There is no minimum PSA for prostatectomy patients. For patients treated with primary radiation therapy PSA should be greater than 2.0 ng/ml * No evidence of recurrent disease on exam, bone scan, CT/MRI abdomen/pelvis or CXR * Prior ADT allowed if \< 6 months and testosterone recovered to within 50 units (ng/dl) of normal range * ECOG Performance status of 0-1 * Absolute neutrophil count of \>1,500 * Platelet count \> 100,000 * Hg \> 8g/dl * No history of bleeding or thromboses within the last 12 months that required medical intervention Exclusion Criteria: * History of cancer within 5 years, other than prostate cancer and non-melanoma skin cancer * Medical condition requiring concomitant corticosteroids * Active infection * Prior chemotherapy allowed if was \< 6 cycles and \> 6 months prior to study entry * Documented local recurrence or metastatic prostate cancer * Inability to comply with study and/or follow-up procedures * Life expectancy of less than 2 years * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study